Research programme: monoclonal antibody therapeutics - Aduro BioTechAlternative Names: BION-1301
Latest Information Update: 08 Feb 2017
At a glance
- Originator Aduro BioTech
- Class Monoclonal antibodies
- Mechanism of Action CD27 antigen inhibitors; CD70 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 modulators; PDCD 1 protein inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
- Research Cancer